Clinica
FDA panel recommends deflating heart balloon pumps risk category; but Abiomed's Impella likely faces stricter regs
06 December 2012
Madeleine Armstrong
Not a subscriber ? Request a FREE Trial
Subscribe to Clinica
RELATED CONTENT
NEWS
Clinica News
- Abiomed receives Impella Class III blow, but might escape cost of new trial
- Abiomed shares slump with news of Impella DoJ investigation
- Abiomed in the clear with FDA over Impella warning letter, but other problems linger
- Thoratec, HeartWare watch out: CardiacAssist starts heart attack trial of percutaneous pump
Other Informa News
EVENTS
Today
UKTI headquarters, 1 Victoria Street, London SW1H 0ET, UK
09 October 2013
Millennium Gloucester Hotel, London, UK
